Maintenance Zanzalintinib With Etoposide After HDCT in GCT
Status:
NOT_YET_RECRUITING
Trial end date:
2032-03-01
Target enrollment:
Participant gender:
Summary
This is an open label, single arm phase I/II trial of maintenance zanzalintinib in combination with oral etoposide in patients with relapsed GCT treated with HDCT and PBSCT with a safety lead-in cohort in patients with relapsed, refractory metastatic GCT.